会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Inhibitor of casein kinase 1δ and casein kinase 1ε
    • 酪蛋白激酶1δ和酪蛋白激酶1抑制剂
    • US09018238B2
    • 2015-04-28
    • US13201309
    • 2009-12-28
    • Masako OkamotoKiyoshi Takayama
    • Masako OkamotoKiyoshi Takayama
    • A61K31/422A61K31/433A61K31/4439C07D413/06C07D413/14C07D417/14C07D413/04C07D263/18
    • C07D413/04A61K31/422A61K31/433A61K31/4439C07D263/18C07D413/06C07D413/14C07D417/14
    • There is provided an inhibitor that inhibits casein kinase 1δ and casein kinase 1ε, and thus, there is also provided a pharmaceutical agent useful for the treatment and/or prevention of a disease, with the pathological condition of which the mechanism of activation of casein kinase 1δ or casein kinase 1ε is associated. Particularly, the above-described inhibitor is used to provide a pharmaceutical agent useful for the treatment of circadian rhythm disorder (including sleep disorder), central neurodegenerative disease, and cancer.An inhibitor of casein kinase 1δ and casein kinase 1ε, which comprises, as an active ingredient, an oxazolone derivative represented by the following general formula (1), a salt thereof, a solvate thereof, or a hydrate thereof: [wherein, in the formula (1), each of R1 and R2 independently represents any one of a substituted or unsubstituted 6-membered or 5-membered heterocyclic group optionally having a condensed ring, a substituted or unsubstituted aromatic hydrocarbon group optionally having a condensed ring, and a substituted or unsubstituted aromatic hydrocarbon lower alkyl group or aromatic hydrocarbon lower alkenyl group optionally having a condensed ring.]
    • 提供了抑制酪蛋白激酶1δ和酪蛋白激酶1的抑制剂,因此,还提供了可用于治疗和/或预防疾病的药剂,其病理状况是酪蛋白的活化机制 激酶1δ或酪蛋白激酶1&egr; 已关联的。 特别地,上述抑制剂用于提供可用于治疗昼夜节律紊乱(包括睡眠障碍),中枢神经变性疾病和癌症的药剂。 酪蛋白激酶1δ和酪蛋白激酶1抑制剂,其包含作为活性成分的由以下通式(1)表示的恶唑酮衍生物,其盐,其溶剂化物或其水合物:[其中,在 式(1)中,R 1和R 2各自独立地表示任选具有稠环的取代或未取代的6元或5元杂环基,任选具有稠环的取代或未取代的芳香族烃基, 取代或未取代的芳烃低级烷基或任选具有稠环的芳烃低级链烯基。
    • 2. 发明授权
    • Inhibitor of casein kinase 1delta and casein kinase 1E
    • 酪蛋白激酶1delta和酪蛋白激酶1E的抑制剂
    • US08710231B2
    • 2014-04-29
    • US13816180
    • 2011-08-08
    • Masako OkamotoKiyoshi Takayama
    • Masako OkamotoKiyoshi Takayama
    • C07D413/00C07D419/00C07D409/00C07D411/00A61K31/44A01N43/40
    • A61K31/4439C07D413/14
    • There is provided a novel oxazolone derivative having inhibitory activity against casein kinase 1δ and casein kinase 1ε. In addition, the present inhibitor inhibits casein kinase 1δ and casein kinase 1ε, and thus there is also provided a pharmaceutical agent useful for the treatment and/or prevention of diseases, with the pathological conditions of which the activation mechanism of casein kinase 1δ or casein kinase 1ε is associated. There is further provided a pharmaceutical agent useful for the treatment of, particularly, circadian rhythm disorder (including sleep disorder), central neurodegenerative disease, and cancer. An inhibitor of casein kinase 1δ and casein kinase 1ε comprising, as an active ingredient, an oxazolone derivative represented by the following general formula (1), a salt thereof, a solvate thereof, or a hydrate thereof: wherein X represents a halogen atom which is fluorine, chlorine, bromine or iodine.
    • 提供了一种对酪蛋白激酶1δ和酪蛋白激酶1具有抑制活性的新型恶唑酮衍生物。 此外,本发明的抑制剂抑制酪蛋白激酶1δ和酪蛋白激酶1和egr,因此还提供了可用于治疗和/或预防疾病的药剂,其病理条件是酪蛋白激酶1δ或 酪蛋白激酶1 已关联的。 还提供了用于治疗,特别是昼夜节律紊乱(包括睡眠障碍),中枢神经变性疾病和癌症的药剂。 酪蛋白激酶1δ和酪蛋白激酶1的抑制剂 作为活性成分,含有下述通式(1)表示的恶唑酮衍生物,其盐,溶剂化物或其水合物:其中,X表示氟,氯,溴或碘的卤素原子。
    • 3. 发明申请
    • INHIBITOR OF CASEIN KINASE 1DELTA AND CASEIN KINASE 1E
    • CASEIN KINASE 1DELTA和CASEIN KINASE 1E的抑制剂
    • US20130137730A1
    • 2013-05-30
    • US13816180
    • 2011-08-08
    • Masako OkamotoKiyoshi Takayama
    • Masako OkamotoKiyoshi Takayama
    • A61K31/4439
    • A61K31/4439C07D413/14
    • There is provided a novel oxazolone derivative having inhibitory activity against casein kinase 1δ and casein kinase 1ε. In addition, the present inhibitor inhibits casein kinase 1δ and casein kinase 1ε, and thus there is also provided a pharmaceutical agent useful for the treatment and/or prevention of diseases, with the pathological conditions of which the activation mechanism of casein kinase 1δ or casein kinase 1ε is associated. There is further provided a pharmaceutical agent useful for the treatment of particularly, circadian rhythm disorder (including sleep disorder), central neurodegenerative disease, and cancer.An inhibitor of casein kinase 1δ and casein kinase 1ε comprising, as an act ingredient, an oxazolone derivative represented by the following general formula (1), a salt thereof, a solvate thereof, or a hydrate thereof: wherein X represents a halogen atom (which may be any one of a fluorine atom, a chlorine atom, a bromine atom, and an iodine atom).
    • 提供了对酪蛋白激酶1delta和酪蛋白激酶1epsilon具有抑制活性的新型恶唑酮衍生物。 此外,本发明的抑制剂抑制酪蛋白激酶1delta和酪蛋白激酶1β,因此还提供了可用于治疗和/或预防疾病的药剂,其病理条件是酪蛋白激酶1delta或酪蛋白的激活机制 激酶1epon是相关的。 还提供了用于特别治疗昼夜节律紊乱(包括睡眠障碍),中枢性神经变性疾病和癌症的药剂。 酪蛋白激酶1delta和酪蛋白激酶1β的抑制剂,其包含作为成分的由以下通式(1)表示的恶唑酮衍生物,其盐,其溶剂合物或其水合物:其中X表示卤素原子( 其可以是氟原子,氯原子,溴原子和碘原子中的任何一个)。
    • 4. 发明申请
    • INHIBITOR OF CASEIN KINASE 1DELTA AND CASEIN KINASE 1EPSILON
    • CASEIN KINASE 1DELTA和CASEIN KINASE 1EPSILON的抑制剂
    • US20110294857A1
    • 2011-12-01
    • US13201309
    • 2009-12-28
    • Masako OkamotoKiyoshi Takayama
    • Masako OkamotoKiyoshi Takayama
    • A61K31/422A61P35/00A61P43/00A61P25/28A61K31/4439A61K31/433
    • C07D413/04A61K31/422A61K31/433A61K31/4439C07D263/18C07D413/06C07D413/14C07D417/14
    • There is provided an inhibitor that inhibits casein kinase 1δ and casein kinase 1ε, and thus, there is also provided a pharmaceutical agent useful for the treatment and/or prevention of a disease, with the pathological condition of which the mechanism of activation of casein kinase 1δ or casein kinase 1ε is associated. Particularly, the above-described inhibitor is used to provide a pharmaceutical agent useful for the treatment of circadian rhythm disorder (including sleep disorder), central neurodegenerative disease, and cancer.An inhibitor of casein kinase 1δ and casein kinase 1ε, which comprises, as an active ingredient, an oxazolone derivative represented by the following general formula (1), a salt thereof, a solvate thereof, or a hydrate thereof: [wherein, in the formula (1), each of R1 and R2 independently represents any one of a substituted or unsubstituted 6-membered or 5-membered heterocyclic group optionally having a condensed ring, a substituted or unsubstituted aromatic hydrocarbon group optionally having a condensed ring, and a substituted or unsubstituted aromatic hydrocarbon lower alkyl group or aromatic hydrocarbon lower alkenyl group optionally having a condensed ring.]
    • 提供了抑制酪蛋白激酶1δ和酪蛋白激酶1的抑制剂,因此,还提供了可用于治疗和/或预防疾病的药剂,其病理状况是酪蛋白的活化机制 激酶1δ或酪蛋白激酶1&egr; 已关联的。 特别地,上述抑制剂用于提供可用于治疗昼夜节律紊乱(包括睡眠障碍),中枢神经变性疾病和癌症的药剂。 酪蛋白激酶1δ和酪蛋白激酶1抑制剂,其包含作为活性成分的由以下通式(1)表示的恶唑酮衍生物,其盐,其溶剂化物或其水合物:[其中,在 式(1)中,R 1和R 2各自独立地表示任选具有稠环的取代或未取代的6元或5元杂环基,任选具有稠环的取代或未取代的芳香族烃基, 取代或未取代的芳烃低级烷基或任选具有稠环的芳烃低级链烯基。